With the possibility that CRISPR-Cas9 could prove ineffective in humans, there was talk that the stocks of these biotechs could turn out to be worthless. But the cart got before the horse — by a few miles.
This year we can expect to see large numbers of CRISPR gene-editing trials, but some are still afraid of this amazing technology.
All on its own, the presence of SRY can make a female turn out to be essentially male—with bigger muscles, a penis, and testicles (although unable to make sperm).
Sinogene, a biotech company based in Beijing has cloned a gene-edited dog in an attempt to treat cardiovascular disease.
Scientists have for the first time used CRISPR to disable a defective gene that causes amyotrophic lateral sclerosis, or Lou Gehrig’s disease, in mice, extending their lifespan by 25 percent.
Copenhagen Center for Glycomics has announced a collaboration with Desktop Genetics to analyse their novel CRISPR assay.
A biotech firm based in Boulder, CO is providing free access to MAD7 a novel enzyme in the gene editing field.
CRISPR Therapeutics is pioneering a new class of medicines, to conduct the first company-sponsored clinical trial of a CRISPR gene-edited therapy.
An adapted CRISPR technique could be used to treat incurable diseases, such as diabetes and muscular dystrophy, by turning up the volume on selected genes.
The US military invests $100m in genetic extinction technologies, after fears rise over channeling gene drives towards bioweaponry.